A Phase 2 interventional study of Venetoclax and Ibrutinib in Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL), sponsored by AbbVie. Completed at 20 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by AbbVie · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell — 8 open to participants now, 28 under way, 4 of them phase 3. ibrutinib · Leukemia, Lymphocytic, Chronic, B-Cell.
Among the 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 64th largest by enrollment, is one of 3 that started in 2021, is one of 43 in phase 2, and was the 77th registered.
2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →8 of the 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–80
Gruppo Italiano Malattie EMatologiche dell'Adulto · Sites in Italy
Ages 18+
Paolo Ghia · Sites in Italy
Ages 18–65
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18–75
Jeanette Lundin · Sites in Norway, Sweden
Ages 18+
By country, each count listing its studies:
ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 51 · Phase 3 15 · Phase 4 1
First in 2010; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 44 across the 83 interventional studies. Of the 44 that completed or were terminated, 26 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 83 have an industry lead sponsor. The 10 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
51 studies in Leukemia, Lymphocytic, Chronic, B-Cell by AbbVie: 3 open now, 11 under way, 2 of them phase 3. Of 38 finished, 18 (47%) have results posted.
Among the 51 studies in Leukemia, Lymphocytic, Chronic, B-Cell by AbbVie, this one is the 35th largest by enrollment of the 39 interventional ones that give a count, is one of 2 that started in 2021, is one of 11 in phase 2, and was the 43rd registered.
AbbVie’s Leukemia, Lymphocytic, Chronic, B-Cell studies by the year they started, since 2004.
6 of the studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01804686Phase 3Janssen Research & Development, LLCA Long-term Extension Study of PCI-32765 (Ibrutinib) | 2026-12-31 |
| NCT03513562Ohio State University Comprehensive Cancer CenterVenetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations | 2026-12-31 |
| NCT03153202Joshua BrodyStudy to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL) | 2027-04 |
| NCT03960840Novartis PharmaceuticalsPhase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL | 2027-06-30 |
| NCT02756897M.D. Anderson Cancer CenterVenetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia | 2027-07-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, from their registry updates:
Among AbbVie’s 51 in Leukemia, Lymphocytic, Chronic, B-Cell:
This tab as a report to print or save as PDF → With an account.
Chronic lymphocytic leukemia (CLL) is the most common leukemia in Western countries, representing approximately 30% of all adult leukemias. There is a large difference in proportion of malignant lymphoma between the United States (US) and Japan was seen in CLL/small lymphocytic lymphoma (SLL) (Japan, 3.2%; US, 24.1%). The purpose of this study is to assess how well venetoclax works in combination with obinutuzumab (V+G, Cohort 1) or with ibrutinib (V+I, Cohort 2) in Japanese participants with previously untreated CLL/Small Lymphocytic Lymphoma (SLL). Adverse events and change in disease activity will be assessed.
Venetoclax is an approved drug for the treatment of CLL and SLL. Study doctors put the participants in 1 of 2 groups, called treatment arms, based on variable alternating assignment. Approximately 20 adult participants with previously untreated CLL/SLL will be enrolled in the study in approximately 20 sites in Japan.
Participants in group 1 will receive oral venetoclax + intravenous (IV) obinutuzumab (V+G) in 28-day cycles for a total of 12 cycles, and participants in group 2 will receive oral venetoclax + oral ibrutinib (V+I) in 28-day cycles for a total of 15 cycles.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, and checking for side effects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adult male or female, at least ≥ 65 years old; or 20 to 64 years old and have at least 1 of the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive venetoclax + obinutuzumab for twelve 28-day cycles.
Drug: Venetoclax · Drug: Obinutuzumab
Participants will receive venetoclax + ibrutinib for fifteen 28-day cycles.
Drug: Venetoclax · Drug: Ibrutinib
Oral Tablet
Also known as: Venclexta, ABT-199, GDC-0199
Oral Capsule
Also known as: Imbruvica
Intravenous (IV) Infusion
Also known as: GA101, Gazyva, RO5072759
Complete Remission (CR) and CR With an Incomplete Marrow Recovery (CRi) Rate Per Independent Review Committee (IRC)
CR+CRi rate was defined as the percentage of participants achieving a best response of CR or CRi as assessed by an IRC per 2008 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria for tumor response. CR required all of the following: * Group A: * Lymphadenopathy: None \> 1.5 centimeters * Blood Lymphocytes: \<4,000/microliter (μL) * Hepatomegaly: None * Splenomegaly: None * Marrow: Normocellular, \< 30% lymphocytes, no B-lymphoid nodules * Group B: * Platelet Count: \> 100,000/μL * Hemoglobin: \> 11.0 grams per deciliter (g/dL) * Neutrophils: \> 1500/μL CRi was defined as a CR with peripheral cytopenia and incomplete recovery of the bone marrow, manifested by persistent cytopenias.
Time frame: Up to 46 months
CR+CRi Rate Per Investigator Assessment
CR+CRi rate was defined as the percentage of participants achieving a best response of CR or CRi as assessed by an IRC per iwCLL criteria for tumor response. CR required all of the following: * Group A: * Lymphadenopathy: None \> 1.5 centimeters * Blood Lymphocytes: \<4,000/μL * Hepatomegaly: None * Splenomegaly: None * Marrow: Normocellular, \< 30% lymphocytes, no B-lymphoid nodules * Group B: * Platelet Count: \> 100,000/μL * Hemoglobin: \> 11.0 g/dL * Neutrophils: \> 1500/μL CRi was defined as a CR with peripheral cytopenia and incomplete recovery of the bone marrow, manifested by persistent cytopenias.
Time frame: Up to 46 months
Overall Response Rate (ORR) Per IRC
ORR was defined as the percentage of participants with a best overall response of CR, CRi, partial remission (PR) or nodular partial remission (nPR) per 2008 iwCLL criteria. PR required at Least 2 Criteria from Group A AND at least 1 Criterion from Group B: * Group A: * Lymphadenopathy: Decrease ≥ 50% * Blood Lymphocytes: Decrease ≥ 50% from baseline * Hepatomegaly: Decrease ≥ 50% * Splenomegaly: Decrease ≥ 50% * Marrow: 50% reduction in marrow infiltrate or B-lymphoid nodules * Group B: * Platelet Count: \> 100,000/μL or increase ≥ 50% over baseline * Hemoglobin: \> 11.0 g/dL or increase ≥ 50% over baseline * Neutrophils: \> 1500/μL or increase ≥ 50% over baseline nPR was a response that met the criteria for CR, but the bone marrow biopsy showed lymphoid nodules, reflecting residual disease.
Time frame: Baseline up to 46 months
ORR Per Investigator Assessment
ORR was defined as the percentage of participants with a best overall response of CR, CRi, PR or nPR per 2008 iwCLL criteria.
Time frame: Baseline up to 46 months
Progression-Free Survival (PFS) Per IRC
PFS was defined as the time from the date of first dose of any study drug until the date of disease progression or death due to any cause, whichever occurred first, according to iwCLL criteria. PFS was analyzed using Kaplan-Meier methodology.
Time frame: Up to 46 months
PFS Per Investigator Assessment
PFS was defined as the time from the date of first dose of any study drug until the date of disease progression or death due to any cause, whichever occurred first, according to iwCLL criteria. PFS was analyzed using Kaplan-Meier methodology.
Time frame: Up to 46 months
Duration of Response (DOR) as Assessed by IRC
DOR was defined as the time from the first occurrence of overall response (CR, CRi, PR or nPR) until disease progression or death due to any cause, whichever occurred first, as determined by an IRC according to iwCLL criteria.
Time frame: Up to 46 months
DOR as Assessed by Investigator
DOR was defined as the time from the first occurrence of overall response (CR, CRi, PR or nPR) until disease progression or death due to any cause, whichever occurred first, as determined by an IRC according to iwCLL criteria.
Time frame: Up to 46 months
Overall Survival (OS)
OS was defined as the time from the date of the first dose of any study drug until death due to any cause.
Time frame: Up to 46 months
Time to Progression (TTP) as Assessed by IRC
TTP was defined as the time from the date of first dose of any study drug until the date of disease progression, as determined by an IRC according to iwCLL criteria.
Time frame: Up to 46 months
TTP as Assessed by Investigator
TTP was defined as the time from the date of first dose of any study drug until the date of disease progression, as determined by an investigator according to iwCLL criteria.
Time frame: Up to 46 months
| Milestone | Venetoclax + Obinutuzumab | Venetoclax + Ibrutinib |
|---|---|---|
| Started | 10 | 10 |
| Received at least 1 dose of study drug | 10 | 10 |
| Completed | 10 | 10 |
| Not completed | 0 | 0 |
CR+CRi rate was defined as the percentage of participants achieving a best response of CR or CRi as assessed by an IRC per 2008 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria for tumor response. CR required all of the following: * Group A: * Lymphadenopathy: None \> 1.5 centimeters * Blood Lymphocytes: \<4,000/microliter (μL) * Hepatomegaly: None * Splenomegaly: None * Marrow: Normocellular, \< 30% lymphocytes, no B-lymphoid nodules * Group B: * Platelet Count: \> 100,000/μL * Hemoglobin: \> 11.0 grams per deciliter (g/dL) * Neutrophils: \> 1500/μL CRi was defined as a CR with peripheral cytopenia and incomplete recovery of the bone marrow, manifested by persistent cytopenias.
| percentage of participants | Venetoclax + Obinutuzumab | Venetoclax + Ibrutinib |
|---|---|---|
| Complete Remission (CR) and CR With an Incomplete Marrow Recovery (CRi) Rate Per Independent Review Committee (IRC) | 100 (69.2 to 100.0) | 80.0 (44.4 to 97.5) |
CR+CRi rate was defined as the percentage of participants achieving a best response of CR or CRi as assessed by an IRC per iwCLL criteria for tumor response. CR required all of the following: * Group A: * Lymphadenopathy: None \> 1.5 centimeters * Blood Lymphocytes: \<4,000/μL * Hepatomegaly: None * Splenomegaly: None * Marrow: Normocellular, \< 30% lymphocytes, no B-lymphoid nodules * Group B: * Platelet Count: \> 100,000/μL * Hemoglobin: \> 11.0 g/dL * Neutrophils: \> 1500/μL CRi was defined as a CR with peripheral cytopenia and incomplete recovery of the bone marrow, manifested by persistent cytopenias.
| percentage of participants | Venetoclax + Obinutuzumab | Venetoclax + Ibrutinib |
|---|---|---|
| CR+CRi Rate Per Investigator Assessment | 90.0 (55.5 to 99.7) | 60.0 (26.2 to 87.8) |
ORR was defined as the percentage of participants with a best overall response of CR, CRi, partial remission (PR) or nodular partial remission (nPR) per 2008 iwCLL criteria. PR required at Least 2 Criteria from Group A AND at least 1 Criterion from Group B: * Group A: * Lymphadenopathy: Decrease ≥ 50% * Blood Lymphocytes: Decrease ≥ 50% from baseline * Hepatomegaly: Decrease ≥ 50% * Splenomegaly: Decrease ≥ 50% * Marrow: 50% reduction in marrow infiltrate or B-lymphoid nodules * Group B: * Platelet Count: \> 100,000/μL or increase ≥ 50% over baseline * Hemoglobin: \> 11.0 g/dL or increase ≥ 50% over baseline * Neutrophils: \> 1500/μL or increase ≥ 50% over baseline nPR was a response that met the criteria for CR, but the bone marrow biopsy showed lymphoid nodules, reflecting residual disease.
| percentage of participants | Venetoclax + Obinutuzumab | Venetoclax + Ibrutinib |
|---|---|---|
| Overall Response Rate (ORR) Per IRC | 100 (69.2 to 100.0) | 100 (69.2 to 100.0) |
ORR was defined as the percentage of participants with a best overall response of CR, CRi, PR or nPR per 2008 iwCLL criteria.
| percentage of participants | Venetoclax + Obinutuzumab | Venetoclax + Ibrutinib |
|---|---|---|
| ORR Per Investigator Assessment | 100 (69.2 to 100.0) | 90.0 (55.5 to 99.7) |
PFS was defined as the time from the date of first dose of any study drug until the date of disease progression or death due to any cause, whichever occurred first, according to iwCLL criteria. PFS was analyzed using Kaplan-Meier methodology.
| months | Venetoclax + Obinutuzumab | Venetoclax + Ibrutinib |
|---|---|---|
| Progression-Free Survival (PFS) Per IRC | NA (NA to NA) | NA (24.6 to NA) |
PFS was defined as the time from the date of first dose of any study drug until the date of disease progression or death due to any cause, whichever occurred first, according to iwCLL criteria. PFS was analyzed using Kaplan-Meier methodology.
| months | Venetoclax + Obinutuzumab | Venetoclax + Ibrutinib |
|---|---|---|
| PFS Per Investigator Assessment | NA (NA to NA) | 31.0 (16.2 to NA) |
DOR was defined as the time from the first occurrence of overall response (CR, CRi, PR or nPR) until disease progression or death due to any cause, whichever occurred first, as determined by an IRC according to iwCLL criteria.
| months | Venetoclax + Obinutuzumab | Venetoclax + Ibrutinib |
|---|---|---|
| Duration of Response (DOR) as Assessed by IRC | NA (NA to NA) | NA (17.3 to NA) |
DOR was defined as the time from the first occurrence of overall response (CR, CRi, PR or nPR) until disease progression or death due to any cause, whichever occurred first, as determined by an IRC according to iwCLL criteria.
| months | Venetoclax + Obinutuzumab | Venetoclax + Ibrutinib |
|---|---|---|
| DOR as Assessed by Investigator | NA (NA to NA) | NA (7.7 to NA) |
OS was defined as the time from the date of the first dose of any study drug until death due to any cause.
| months | Venetoclax + Obinutuzumab | Venetoclax + Ibrutinib |
|---|---|---|
| Overall Survival (OS) | NA (NA to NA) | NA (NA to NA) |
TTP was defined as the time from the date of first dose of any study drug until the date of disease progression, as determined by an IRC according to iwCLL criteria.
| months | Venetoclax + Obinutuzumab | Venetoclax + Ibrutinib |
|---|---|---|
| Time to Progression (TTP) as Assessed by IRC | NA (NA to NA) | NA (24.6 to NA) |
TTP was defined as the time from the date of first dose of any study drug until the date of disease progression, as determined by an investigator according to iwCLL criteria.
| months | Venetoclax + Obinutuzumab | Venetoclax + Ibrutinib |
|---|---|---|
| TTP as Assessed by Investigator | NA (NA to NA) | 31.0 (16.2 to NA) |
Collected over All-cause mortality and adverse event tables include events reported from the start of safety data collection to the end of the study. The median time on follow-up was 1134.5 and 1172.5 days for arms Venetoclax + Obinutuzumab and Venetoclax + Ibrutinib respectively.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Venetoclax + Obinutuzumab | 0/10 (0%) | 5/10 (50%) | 10/10 (100%) |
| Venetoclax + Ibrutinib | 0/10 (0%) | 3/10 (30%) | 10/10 (100%) |
| Event | Venetoclax + Obinutuzumab | Venetoclax + Ibrutinib |
|---|---|---|
| FEBRILE NEUTROPENIABlood and lymphatic system disorders | 1/10 | 1/10 |
| ATRIAL FIBRILLATIONCardiac disorders | 0/10 | 1/10 |
| MACULAR HOLEEye disorders | 1/10 | 0/10 |
| ABSCESS LIMBInfections and infestations | 0/10 | 1/10 |
| COVID-19Infections and infestations | 0/10 | 1/10 |
| HEPATITIS B REACTIVATIONInfections and infestations | 1/10 | 0/10 |
| PNEUMONIA BACTERIALInfections and infestations | 1/10 | 0/10 |
| PNEUMONIA MYCOPLASMALInfections and infestations | 1/10 | 0/10 |
| BLOOD CREATINE PHOSPHOKINASE INCREASEDInvestigations | 0/10 | 1/10 |
| URETEROLITHIASISRenal and urinary disorders | 1/10 | 0/10 |
| Event | Venetoclax + Obinutuzumab | Venetoclax + Ibrutinib |
|---|---|---|
| INFUSION RELATED REACTIONInjury, poisoning and procedural complications | 6/10 | 0/10 |
| NEUTROPHIL COUNT DECREASEDInvestigations | 5/10 | 4/10 |
| RASHSkin and subcutaneous tissue disorders | 0/10 | 5/10 |
| DIARRHOEAGastrointestinal disorders | 3/10 | 4/10 |
| NAUSEAGastrointestinal disorders | 4/10 | 4/10 |
| PYREXIAGeneral disorders | 4/10 | 0/10 |
| COVID-19Infections and infestations | 4/10 | 2/10 |
| ANAEMIABlood and lymphatic system disorders | 3/10 | 1/10 |
| LEUKOPENIABlood and lymphatic system disorders | 3/10 | 0/10 |
| LYMPHOPENIABlood and lymphatic system disorders | 3/10 | 1/10 |
The full analysis set (FAS) included all participants who received at least 1 dose of study drug.
| Age, Categorical(Participants) | Venetoclax + Obinutuzumab | Venetoclax + Ibrutinib | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 4 | 1 | 5 |
| >=65 years | 6 | 9 | 15 |
| Sex: Female, Male(Participants) | Venetoclax + Obinutuzumab | Venetoclax + Ibrutinib | Total |
|---|---|---|---|
| Female | 4 | 4 | 8 |
| Male | 6 | 6 | 12 |
| Race (NIH/OMB)(Participants) | Venetoclax + Obinutuzumab | Venetoclax + Ibrutinib | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 10 | 10 | 20 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Venetoclax + Obinutuzumab | Venetoclax + Ibrutinib | Total |
|---|---|---|---|
| Japanese | 10 | 10 | 20 |
| Chinese | 0 | 0 | 0 |
| Korean | 0 | 0 | 0 |
| Taiwanese | 0 | 0 | 0 |
| Other | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
Supporting information: Study protocol, Statistical analysis plan
Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Data sharing details ↗ · vivli.org
Ran from Nov 2021 to primary completion in Oct 2025, 47 months.
Results were first posted in Oct 2026, 1 year after primary completion.
Of 41 industry-sponsored phase 2 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 87. This study's 47 months is below that.
Counting every sponsor, half of 249 studies reached it within 73 months; a quarter within 41 and three quarters within 114.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ibrutinib · Obinutuzumab
Leukemia, Lymphocytic, Chronic, B-Cell →